By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
PHARMA JOBS POSTPHARMA JOBS POSTPHARMA JOBS POST
  • HOME
  • FRESHERS
  • LOCATIONS
  • ABOUT US
  • CONTACT
  • DISCLAIMER
Notification
PHARMA JOBS POSTPHARMA JOBS POST
  • HOME
  • FRESHERS
  • LOCATIONS
  • ABOUT US
  • CONTACT
  • DISCLAIMER
Have an existing account? Sign In
Follow US
PHARMA JOBS POST © 2024 All Rights Reserved.
WhatsApp Group Join Now
Telegram Group Join Now
- Advertisement -
Ad imageAd image
Ad imageAd image
PHARMA JOBS POST > Global Pharma News > Biocon plans $150-million capex in two years
Global Pharma NewsInvestment

Biocon plans $150-million capex in two years

Newspress
Last updated: May 12, 2025 12:54 am
Newspress 3 weeks ago 316 Views
Share
SHARE

Biopharmaceutical firm Biocon plans to invest $150 million in capital expenditures over the next couple of years, with $100 million earmarked for its biologics division and the remaining for the generics business, top company officials said.

A large part of the biologics investment “will go to enhance the capacities in Malaysia,” Kedar Upadhye, chief financial officer of Biocon Biologics, told analysts in an earnings call on Friday. Capex in biologics is expected to get moderated after a couple of years, he said.

Siddharth Mittal, managing director and chief executive officer of Biocon, said, “For generics, we will be looking at $50 million capex next year and with that, majority of our ongoing capex programmes will come to an end and there will be a small bit of maintenance capex going forward.”

Biocon had on Thursday announced its fourth quarter result with a 153% surge in net profit to Rs 344 crore, while consolidated total revenue for Q4 was Rs 4,454 crore, a growth of 12% the previous year.

“This quarter’s performance was bolstered by strong growth in generics, steady progress in biosimilars and ongoing traction in research services,” Kiran Mazumdar-Shaw, chairperson, Biocon Group, said at the analyst call.

During the quarter, Biocon launched lenalidomide – a medication used to treat types of multiple myeloma – and oncology drug dasatinib in the US, and anti-diabetes medication liraglutide in the UK.

One of the primary focus areas for the company going ahead will be its peptide portfolios, especially GLP1s which it sees as the key driver of future growth.

The company is also betting big on its biosimilars that continued to build shares in global markets with four biosimilars recording sales of $200 million each in FY25.

It plans to launch oncology drug bevacizumab in the US in the first half of this year when it also expects approval for diabetes drug insulin aspart, according to Matthew Erick, chief commercial officer – advanced markets at Biocon Biologics. “We have an incredible oncology portfolio and it will be a nice addition to our portfolio and we will be well positioned with our sales force,” he said.

It has already launched yesintek (biosimilar Ustekinumab), one of the first biosimilars to Stelara in the US.

Analysts have maintained a strong near-to-mid-term outlook on the company based on multiple recent product launches and planned launches this year.

“Biocon Q4 result was strong and just in line with our estimates, driven by the launch of gRevlimid and Dasatinib in the US,” PhillipCapital’s pharma analyst Surya Patra said in a report.

He said they remain optimistic about the company, citing a strong biosimilar pipeline and recent clearance of Bengaluru and Malaysia facilities, “paving the way for the launch of Bevacizumab, Insulin aspart biosimilars in the US.”

Additionally, the recent launch of ustekinumab biosimilar (a drug used to treat autoimmune conditions) and strong positioning of biosimilar aflibercept (used to treat eye conditions) in the US augurs well for the company, Patra added.

It received approvals for liraglutide in the EU, and everolimus (Zortress) tablets in the US. It partnered with Civica Inc, a US-based not-for-profit, supporting affordable insulin access for people with diabetes.

“With a surge in global insulin demand, given our global scale manufacturing capacities, we are well-positioned to capitalise on this large opportunity,” Shaw said.

During the quarter, the company’s arm Syngene expanded its biologics manufacturing footprint through an acquisition of a facility in the US.

The company is also looking at raising Rs 4,500 crore through a combination of QIP and private placement. The proceeds of the funds raised will be primarily used to meet financial obligations towards commitments and put options from the structured debt that the company has from investments in its biologics unit.

WhatsApp Group Join Now
Telegram Group Join Now
- Advertisement -
DEFINE ACADEMY DRUG REGULATORY AFFAIRSDEFINE ACADEMY DRUG REGULATORY AFFAIRS
TAGGED: Announcement, Biocon, Capital expenditures, Indian pharma market, Investment, pharma news
Share This Article
Facebook Twitter LinkedIn Email Print
Previous Article APL Healthcare Limited – Walk-In Drive for Production & Packing Roles (Technical Assistants, Executives) on 11th May 2025
Next Article FDC recalls over 60,000 bottles of ophthalmic solution in US

RECENT POSTS

  • Join Vital Group – Exciting Job Openings Across Various Departments
  • Acme Generics is Hiring: Quality Assurance Roles Open Now
  • Neuron Pharma Hiring QC Micro Executive – Apply Now
  • Walk-In Drive at Chemveda Life Sciences – Hiring Research Associates in Hyderabad (June 7, 2025)
  • Walk-In Interview at Cadila Pharmaceuticals: Production, QA/QC, Engineering Jobs – 8th June – Pithampur, Madhya Pradesh
  • Join Juvencia’s Regulatory Affairs Team – Now Hiring Experts!
  • Biological E Ltd walk in:June 1 for QA, QC, Microbiology, Engineering & Production Jobs
  • Join Spectrasynth! Fresher Walk-In Interview on 1st June for QA, R&D, ADL & Marketing
  • Zydus Walk-In Interview on June 1 for Production, Engineering & Warehouse Jobs
  • Annora Pharma Hiring Freshers,Walk-In on on June 5, 2025 for Male Apprentices in Hyderabad
  • Freshers Opportunity: Sun Pharma Apprentice Recruitment in Dewas – Apply Now
  • Join Ichor Biologics: R&D Head – Plasma-Derived Therapies & Biosimilars | Hyderabad-Based Role
  • Walk-In Interview at Aurobindo Pharma – Hiring for Production, QA, QC & Packing | 1st June 2025, Hyderabad
JOIN WHATSAPP CHANNEL

Recent Jobs

  • Amgen

    Entry-Level Role at Amgen: Associate IS – Signal & Risk Management (Freshers Eligible)

    • India - Hyderabad
    • Amgen
  • Clarivate

    Freshers in Pharmacy/ Life Sciences – Explore Your Future at Clarivate

    • Noida, Uttar Pradesh, India
    • Clarivate
  • Gland Pharma Ltd.

    Gland Pharma’s Mega Hiring Drive for Quality Professionals on 7th June 2025 (Saturday) – Don’t Miss It!

    • Dundigal, Hyderabad
    • Gland Pharma Ltd.
  • Amoli Organics

    24 Job Openings at Amoli Organics – Walk-In at Boisar on 1st June 2025

    • Boisar, Maharashtra
    • Amoli Organics
  • Ayur.AI

    Clinical Research Job for Freshers – Full-Time Role at Ayur.AI

    • Siruseri, Chennai
    • Ayur.AI
  • Mylan Laboratories Limited

    Mylan Laboratories to Conduct Walk-In Interviews for Injectable Manufacturing Roles in Hosur

    • Hosur, Krishnagiri, Tamil Nadu
    • Mylan Laboratories Limited
  • Cadila Pharmaceuticals

    Pharma R&D Jobs: Analyst Vacancy in Analytical Research Laboratory (0–4 Years Exp) at Cadila Pharmaceuticals

    • Dholka, Ahmedabad
    • Cadila Pharmaceuticals
  • Lupin Biotech

    Lupin Biotech to Conduct Walk-in Interviews in Pune for QA, QC, and Biosimilars Roles

    • Pune, Maharashtra
    • Lupin Biotech
  • Ajanta Pharma Ltd.

    Ajanta Pharma Ltd Announces Walk-In Interviews for Multiple Roles at US FDA Approved Facility in Maharashtra

    • Chhatrapati Sambhajinagar
    • Ajanta Pharma Ltd.
  • Evertogen Lifesciences Ltd.

    Evertogen Lifesciences Ltd. Invites Fresh Talent to Join Its Team at Jadcherla Facility

    • Jadcherla
    • Evertogen Lifesciences Ltd.
  • Cadila Pharmaceuticals

    We’re Hiring: Research Associate / Sr. Research Associate – Formulation Development (Injectables)

    • Dholka, Ahmedabad
    • Cadila Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.

    Sun Pharma – Dewas is Hiring: Wruster Coating Supervisor Wanted

    • Dewas, Madhya Pradesh
    • Sun Pharmaceutical Industries Ltd.

Tags

Ahmedabad (65) ahmedabad pharma jobs (189) ahmedabad pharma vacancy (165) ahmedabad pharma walk in interview (89) Baddi Pharma Vacancy (59) Bangalore pharma company jobs (41) Bangalore pharma jobs (31) FRESHERS (181) freshers jobs in pharma industry (50) freshers pharmacy jobs (46) goa pharma company job (27) Hiring (119) Hiring jobs (463) Hyderabad (57) hyderabad pharma company jobs (184) hyderabad pharma jobs (94) hyderabad pharma jobs freshers (42) hyderabad pharma vacancies (111) hyd pharma jobs (31) indore pharma company vacancy (27) job alert (384) job Opportunity (246) Job search (462) job Vaccancy (452) Mumbai Pharma company jobs (34) Pharmacovigilance Jobs vacancy (38) Pharma jobs (104) Pharma jobs at Baddi (36) pharma jobs in hyderabad (84) Pharma QA Jobs (35) pharma qa vacancy (28) pharma vacancy in ahmedabad (30) pharma walk in interview (44) Production (58) Production Department (73) QA (53) QC (77) QC Department (45) Quality Control (QC) (32) Regulatory Affairs (55) Regulatory Affairs Jobs Vacancy (63) Vadodara (33) Vadodara Pharma Job Vacancy (53) Walk In Drive (125) Walk In Interview (180)
PHARMA JOBS POSTPHARMA JOBS POST
Follow US
PHARMA JOBS POST © 2024 All Rights Reserved.
JOIN OUR WHATSAPP GROUP
JOIN OUR TELEGRAM GROUP
Welcome Back!

Sign in to your account

Lost your password?